• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

肝细胞癌的靶向治疗：利用乳糖化 pH 响应性纳米粒共递送索拉非尼和姜黄素。

Targeted Therapy for Hepatocellular Carcinoma: Co-Delivery of Sorafenib and Curcumin Using Lactosylated pH-Responsive Nanoparticles.

机构信息

Department of Pharmacy, Affiliated Hospital of Jiangnan University, The Fourth People's Hospital of Wuxi City, WuXi 214000, Jiangsu Province, People's Republic of China.

Affiliated Hospital of Jiangnan University, The Fourth People's Hospital of Wuxi City, Wuxi 214000, Jiangsu Province, People's Republic of China.

出版信息

Drug Des Devel Ther. 2020 Feb 18;14:647-659. doi: 10.2147/DDDT.S238955. eCollection 2020.

DOI:10.2147/DDDT.S238955
PMID:32109990
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7035906/
Abstract

PURPOSE

Hepatocellular carcinoma (HCC) is a leading cancer worldwide. In the present investigation, sorafenib (SFN) and curcumin (CCM) were co-delivered using pH-sensitive lactosylated nanoparticles (LAC-NPs) for targeted HCC treatment.

METHODS

pH-responsive lactosylated materials were synthesized. SFN and CCM co-delivered, pH-responsive lactosylated nanoparticles (LAC-SFN/CCM-NPs) were self-assembled by using the nanoprecipitation technique. The nanoparticles were characterized in terms of particle size, charge and drug release profile. The anti-cancer effects of the nanoparticles were evaluated in human hepatic carcinoma cells (HepG2) cells and HCC tumor xenograft models.

RESULTS

LAC-SFN/CCM-NPs are spherical particles with light coats on the surface. The size and zeta potential of LAC-SFN/CCM-NPs were 115.5 ± 3.6 nm and -34.6 ± 2.4, respectively. The drug release of LAC-SFN/CCM-NPs in pH 5.5 was more efficient than in pH 7.4. LAC-SFN/CCM-NPs group exhibited the smallest tumor volume (239 ± 14 mm), and the inhibition rate of LAC-SFN/CCM-NPs was 77.4%.

CONCLUSION

In summary, LAC-SFN/CCM-NPs was proved to be a promising system for targeted HCC therapy.

摘要

目的

肝细胞癌（HCC）是全球主要的癌症之一。在本研究中，采用 pH 敏感的乳糖化纳米粒（LAC-NPs）共载索拉非尼（SFN）和姜黄素（CCM），用于靶向 HCC 治疗。

方法

合成 pH 响应性乳糖化材料。采用纳米沉淀技术自组装 SFN 和 CCM 共载、pH 响应性乳糖化纳米粒（LAC-SFN/CCM-NPs）。从粒径、电荷和药物释放曲线等方面对纳米粒进行了表征。在人肝癌细胞（HepG2）和 HCC 肿瘤异种移植模型中评价了纳米粒的抗癌作用。

结果

LAC-SFN/CCM-NPs 为表面有轻微涂层的球形颗粒。LAC-SFN/CCM-NPs 的粒径和 Zeta 电位分别为 115.5±3.6nm 和-34.6±2.4。LAC-SFN/CCM-NPs 在 pH5.5 下的药物释放效率高于 pH7.4。LAC-SFN/CCM-NPs 组的肿瘤体积最小（239±14mm），抑制率为 77.4%。

结论

总之，LAC-SFN/CCM-NPs 被证明是一种有前途的靶向 HCC 治疗系统。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c769/7035906/c1b597f3d227/DDDT-14-647-g0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c769/7035906/119793b5fff3/DDDT-14-647-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c769/7035906/e9d3b7e5ab05/DDDT-14-647-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c769/7035906/9a71ce70085b/DDDT-14-647-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c769/7035906/6646b3b32583/DDDT-14-647-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c769/7035906/5b45c4fc3d41/DDDT-14-647-g0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c769/7035906/08dbf951ae47/DDDT-14-647-g0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c769/7035906/eb0289773ff1/DDDT-14-647-g0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c769/7035906/260b7320f417/DDDT-14-647-g0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c769/7035906/c1b597f3d227/DDDT-14-647-g0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c769/7035906/119793b5fff3/DDDT-14-647-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c769/7035906/e9d3b7e5ab05/DDDT-14-647-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c769/7035906/9a71ce70085b/DDDT-14-647-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c769/7035906/6646b3b32583/DDDT-14-647-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c769/7035906/5b45c4fc3d41/DDDT-14-647-g0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c769/7035906/08dbf951ae47/DDDT-14-647-g0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c769/7035906/eb0289773ff1/DDDT-14-647-g0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c769/7035906/260b7320f417/DDDT-14-647-g0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c769/7035906/c1b597f3d227/DDDT-14-647-g0009.jpg

相似文献

1
Targeted Therapy for Hepatocellular Carcinoma: Co-Delivery of Sorafenib and Curcumin Using Lactosylated pH-Responsive Nanoparticles.肝细胞癌的靶向治疗：利用乳糖化 pH 响应性纳米粒共递送索拉非尼和姜黄素。
Drug Des Devel Ther. 2020 Feb 18;14:647-659. doi: 10.2147/DDDT.S238955. eCollection 2020.
2
Targeted and synergistic therapy for hepatocellular carcinoma: monosaccharide modified lipid nanoparticles for the co-delivery of doxorubicin and sorafenib.肝细胞癌的靶向协同治疗：用于阿霉素和索拉非尼共递送的单糖修饰脂质纳米粒
Drug Des Devel Ther. 2018 Jul 11;12:2149-2161. doi: 10.2147/DDDT.S166402. eCollection 2018.
3
Curcumin-loaded galactosylated BSA nanoparticles as targeted drug delivery carriers inhibit hepatocellular carcinoma cell proliferation and migration.载姜黄素的半乳糖化牛血清白蛋白纳米粒作为靶向药物传递载体抑制肝癌细胞增殖和迁移。
Int J Nanomedicine. 2018 Dec 6;13:8309-8323. doi: 10.2147/IJN.S184379. eCollection 2018.
4
Microbiota-derived SSL6 enhances the sensitivity of hepatocellular carcinoma to sorafenib by down-regulating glycolysis.肠道菌群衍生的 SSL6 通过下调糖酵解增强肝癌对索拉非尼的敏感性。
Cancer Lett. 2020 Jul 1;481:32-44. doi: 10.1016/j.canlet.2020.03.027. Epub 2020 Apr 1.
5
Enhancing anti-tumor efficiency in hepatocellular carcinoma through the autophagy inhibition by miR-375/sorafenib in lipid-coated calcium carbonate nanoparticles.通过脂质包覆碳酸钙纳米粒子中的 miR-375/索拉非尼抑制自噬来增强肝癌的抗肿瘤效率。
Acta Biomater. 2018 May;72:248-255. doi: 10.1016/j.actbio.2018.03.022. Epub 2018 Mar 17.
6
Doxorubicin and curcumin co-delivery by lipid nanoparticles for enhanced treatment of diethylnitrosamine-induced hepatocellular carcinoma in mice.脂质纳米粒共递送阿霉素和姜黄素增强治疗小鼠二乙基亚硝胺诱导的肝细胞癌
Eur J Pharm Biopharm. 2015 Jun;93:27-36. doi: 10.1016/j.ejpb.2015.03.003. Epub 2015 Mar 11.
7
Codelivery of sorafenib and curcumin by directed self-assembled nanoparticles enhances therapeutic effect on hepatocellular carcinoma.索拉非尼和姜黄素通过定向自组装纳米颗粒的共递送增强对肝细胞癌的治疗效果。
Mol Pharm. 2015 Mar 2;12(3):922-31. doi: 10.1021/mp500755j. Epub 2015 Feb 5.
8
Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib.载sorafenib 和米非司酮的 CXCR4 靶向 PLGA-PEG 纳米粒共递送克服了肝细胞癌对 sorafenib 的耐药性。
J Exp Clin Cancer Res. 2019 May 31;38(1):232. doi: 10.1186/s13046-019-1216-x.
9
Resistance of hepatocellular carcinoma to sorafenib can be overcome with co-delivery of PI3K/mTOR inhibitor BEZ235 and sorafenib in nanoparticles.纳米粒共递送 PI3K/mTOR 抑制剂 BEZ235 和索拉非尼可克服肝细胞癌对索拉非尼的耐药性。
Expert Opin Drug Deliv. 2020 Apr;17(4):573-587. doi: 10.1080/17425247.2020.1730809. Epub 2020 Feb 23.
10
Enhancing Anti-Tumor Activity of Sorafenib Mesoporous Silica Nanomatrix in Metastatic Breast Tumor and Hepatocellular Carcinoma via the Co-Administration with Flufenamic Acid.通过与氟芬那酸联合给药增强索拉非尼介孔硅纳米基质在转移性乳腺癌和肝癌中的抗肿瘤活性。
Int J Nanomedicine. 2020 Mar 16;15:1809-1821. doi: 10.2147/IJN.S240436. eCollection 2020.

引用本文的文献

1
Responsive biomaterials for therapeutic strategies of hepatocellular carcinoma.用于肝细胞癌治疗策略的响应性生物材料
Front Bioeng Biotechnol. 2025 Aug 20;13:1673134. doi: 10.3389/fbioe.2025.1673134. eCollection 2025.
2
Precision targeting in hepatocellular carcinoma: Exploring ligand-receptor mediated nanotherapy.肝细胞癌中的精准靶向：探索配体-受体介导的纳米疗法。
World J Hepatol. 2024 Feb 27;16(2):164-176. doi: 10.4254/wjh.v16.i2.164.
3
Role of Phytoconstituents in Cancer Treatment: A Review.植物成分在癌症治疗中的作用：综述

本文引用的文献

1
Homotypic Cell Membrane-Cloaked Biomimetic Nanocarrier for the Targeted Chemotherapy of Hepatocellular Carcinoma.同质细胞膜伪装仿生纳米载体用于肝细胞癌的靶向化疗。
Theranostics. 2019 Aug 12;9(20):5828-5838. doi: 10.7150/thno.34837. eCollection 2019.
2
Nanomedicine as a putative approach for active targeting of hepatocellular carcinoma.纳米医学作为一种有前途的主动靶向肝癌的方法。
Semin Cancer Biol. 2021 Feb;69:91-99. doi: 10.1016/j.semcancer.2019.08.016. Epub 2019 Aug 14.
3
Chlorin e6-Loaded PEG-PCL Nanoemulsion for Photodynamic Therapy and In Vivo Drug Delivery.
Recent Adv Food Nutr Agric. 2024;15(2):115-137. doi: 10.2174/012772574X274566231220051254.
4
Nanoformulated 3'-diindolylmethane modulates apoptosis, migration, and angiogenesis in breast cancer cells.纳米制剂化的3'-二吲哚基甲烷调节乳腺癌细胞的凋亡、迁移和血管生成。
Heliyon. 2023 Dec 10;10(1):e23553. doi: 10.1016/j.heliyon.2023.e23553. eCollection 2024 Jan 15.
5
Co-Encapsulation of Curcumin and Diosmetin in Nanoparticles Formed by Plant-Food-Protein Interaction Using a pH-Driven Method.采用pH驱动法通过植物-食物-蛋白质相互作用形成的纳米颗粒中姜黄素与香叶木素的共包封
Foods. 2023 Jul 27;12(15):2861. doi: 10.3390/foods12152861.
6
Construction of a Ternary Composite Colloidal Structure of Zein/Soy Protein Isolate/Sodium Carboxymethyl Cellulose to Deliver Curcumin and Improve Its Bioavailability.构建玉米醇溶蛋白/大豆分离蛋白/羧甲基纤维素三元复合胶体结构以递送姜黄素并提高其生物利用度。
Foods. 2023 Jul 13;12(14):2692. doi: 10.3390/foods12142692.
7
Advances in the Study of Bioactive Nanoparticles for the Treatment of HCC and Its Postoperative Residual Cancer.用于 HCC 及其术后残余癌治疗的生物活性纳米粒子的研究进展。
Int J Nanomedicine. 2023 May 22;18:2721-2735. doi: 10.2147/IJN.S399146. eCollection 2023.
8
Effect of the COVID-19 Pandemic on the Psychological Health of Patients Who Underwent Liver Transplantation Due to Hepatocellular Carcinoma.2019年冠状病毒病大流行对因肝细胞癌接受肝移植患者心理健康的影响。
Diagnostics (Basel). 2023 Apr 13;13(8):1410. doi: 10.3390/diagnostics13081410.
9
Codelivery of Phytochemicals with Conventional Anticancer Drugs in Form of Nanocarriers.纳米载体形式的植物化学物质与传统抗癌药物的共递送
Pharmaceutics. 2023 Mar 9;15(3):889. doi: 10.3390/pharmaceutics15030889.
10
Natural Products as Anticancer Agents: Current Status and Future Perspectives.天然产物作为抗癌剂：现状与展望。
Molecules. 2022 Nov 30;27(23):8367. doi: 10.3390/molecules27238367.
载氯乙啶-PEG-PCL 纳米乳用于光动力疗法和体内药物递送。
Int J Mol Sci. 2019 Aug 14;20(16):3958. doi: 10.3390/ijms20163958.
4
In vitro and in vivo effect of hyaluronic acid modified, doxorubicin and gallic acid co-delivered lipid-polymeric hybrid nano-system for leukemia therapy.透明质酸修饰的阿霉素和没食子酸共递送脂质-聚合物杂化纳米系统对白血病治疗的体内外作用
Drug Des Devel Ther. 2019 Jun 28;13:2043-2055. doi: 10.2147/DDDT.S202818. eCollection 2019.
5
Synergism of cisplatin-oleanolic acid co-loaded calcium carbonate nanoparticles on hepatocellular carcinoma cells for enhanced apoptosis and reduced hepatotoxicity.载顺铂-齐墩果酸碳酸钙纳米粒对肝癌细胞的协同作用增强凋亡，降低肝毒性。
Int J Nanomedicine. 2019 May 28;14:3753-3771. doi: 10.2147/IJN.S196651. eCollection 2019.
6
Curcumin-Loaded Mesoporous Silica Nanoparticles Markedly Enhanced Cytotoxicity in Hepatocellular Carcinoma Cells.载姜黄素介孔硅纳米粒子显著增强肝癌细胞的细胞毒性。
Int J Mol Sci. 2019 Jun 14;20(12):2918. doi: 10.3390/ijms20122918.
7
In vitro and in vivo mechanism of hepatocellular carcinoma inhibition by β-TCP nanoparticles.β-TCP 纳米颗粒体外和体内抑制肝癌的机制。
Int J Nanomedicine. 2019 May 13;14:3491-3502. doi: 10.2147/IJN.S193192. eCollection 2019.
8
Fabrication of cRGD-modified reduction-sensitive nanocapsule via Pickering emulsion route to facilitate tumor-targeted delivery.通过 Pickering 乳液途径制备 cRGD 修饰的还原敏感纳米胶囊，以促进肿瘤靶向递药。
Int J Nanomedicine. 2019 May 8;14:3361-3373. doi: 10.2147/IJN.S202063. eCollection 2019.
9
Improving breast cancer therapy using doxorubicin loaded solid lipid nanoparticles: Synthesis of a novel arginine-glycine-aspartic tripeptide conjugated, pH sensitive lipid and evaluation of the nanomedicine in vitro and in vivo.利用载多柔比星固体脂质纳米粒改善乳腺癌治疗：新型精氨酸-甘氨酸-天冬氨酸三肽偶联、pH 敏感脂质的合成及纳米药物的体内外评价。
Biomed Pharmacother. 2019 Aug;116:109006. doi: 10.1016/j.biopha.2019.109006. Epub 2019 May 29.
10
Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib.载sorafenib 和米非司酮的 CXCR4 靶向 PLGA-PEG 纳米粒共递送克服了肝细胞癌对 sorafenib 的耐药性。
J Exp Clin Cancer Res. 2019 May 31;38(1):232. doi: 10.1186/s13046-019-1216-x.